Product
SPH4336
Aliases
SPH4336 Tablets, SPH4336 Tablets Placebo
6 clinical trials
5 indications
Indication
Breast Cancer Brain MetastasesIndication
LiposarcomaIndication
DedifferentiatedIndication
CancerClinical trial
A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitor Combined With Endocrine TherapyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic LiposarcomasStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
An Open-label, Dose-escalation, Phase I Clinical Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Open-label, Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors, Including Advanced Well Differentiated/Dedifferentiated Liposarcoma.Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Randomized, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-08-18